Publication: Role of omalizumab in a patient with hyper-IgE syndrome and review dermatologic manifestations
Issued Date
2009-12-01
Resource Type
ISSN
0125877X
Other identifier(s)
2-s2.0-77953626683
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asian Pacific Journal of Allergy and Immunology. Vol.27, No.4 (2009), 233-236
Suggested Citation
Leena Chularojanamontri, Saranjit Wimoolchart, Papapit Tuchinda, Kanokvalai Kulthanan, Nisa Kiewjoy Role of omalizumab in a patient with hyper-IgE syndrome and review dermatologic manifestations. Asian Pacific Journal of Allergy and Immunology. Vol.27, No.4 (2009), 233-236. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/27615
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Role of omalizumab in a patient with hyper-IgE syndrome and review dermatologic manifestations
Other Contributor(s)
Abstract
Hyper-IgE syndrome (HIES) is a rare idiopathic primary immunodeficiency. It is characterized by a triad of findings, including high levels of serum IgE, recurrent skin abscesses and pneumonia and leads to pneumatocele formation. The diagnosis of HIES is complicated by a diversity of clinical and immunological spectrums and a heterogeneous set of genetic defects. The National Institute of Health (NIH) developed a scoring system for HIES in which a score greater than 14 indicates a probable diagnosis. Our patient presented with recurrent multiple abscesses on her scalp, recalcitrant eczema, candida onychomycosis, alopecia universalis, and highly elevated levels of serum IgE. Using the NIH scoring system, a 30 total-point score in this patient indicated the likelihood of carrying the HIES genotype. To our knowledge, there are no specific treatments of HIES. The humanized recombinant mo-noclonal antibody against IgE, subcutaneous omalizumab, was successfully used in this patient.